Latest press releases
Meet NiCoLA-B – the most advanced drug discovery robot in the world
Quietly and efficiently, NiCoLA-B swings into action, ready to test up to 300,000 compounds a day in the quest to identify life saving new medicines. The world’s most advanced drug discovery robot is working alongside our scientists to help make drug discovery smarter, faster and cheaper. Designed to work three times more quickly than previous drug discovery robots, NiCoLA-B is also more scientist-friendly, flexible and responsive.
Joining forces with academia to discover novel chemistry approaches
We have been partnering with the Max-Planck Society and consortium companies for several years. In 2014, we established a chemistry ‘satellite unit’ for cardiovascular and metabolic diseases at the Max Planck Institute of Molecular Physiology in Dortmund, Germany. Here, AstraZeneca scientists are working side-by-side with academic researchers to study new modalities chemistry. This novel strategic alliance aims to discover innovative approaches to drug discovery by combining the strengths of industry and academia. Our focus is on novel chemistry and chemical biology in areas of new modality chemistry such as stabilised peptides, macrocycles and conjugation chemistry.
My lung cancer journey
LabTalk blog post by Dr Denny Clifford - “Early in my career as a practicing Pulmonary and Critical Care specialist I was fortunate to be a Principal Investigator on an AstraZeneca study, which led to a long relationship investigating new pharmaceuticals in the Respiratory field. In my 33 years as a practicing doctor I have diagnosed over 800 lung cancers, and dedicated my time to providing patients with the best possible care.”
Harnessing personalised healthcare to identify novel therapeutic targets for Chronic Kidney Disease (CKD) patients
Each November, more than 13,000 leading nephrologists and other medical and scientific professionals from around the world present and discuss the latest advances and challenges in kidney research and treatment at the American Society of Nephrology Kidney Week. This year, with a steadily growing presence, AstraZeneca is presenting five abstracts from our early science research teams alone that unveil new evidence for novel, potential chronic kidney disease (CKD) drug targets that leverage our personalised healthcare approach.
AstraZeneca climbs eight positions in Access to Medicine Index
The highest climber in the 2016 Index, AstraZeneca is now ranked seventh overall in providing access to medicine. The Access to Medicines Index ranks the top 20 pharmaceutical companies based on their access-to-medicine performance for high-burden diseases in low- and middle-income countries.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Page Atlas ID: 970733.011.
Date of next review: April 2017